Visualitza per autor "Wildiers, Hans"
Ara mostrant els elements 1-4 d 4
-
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Matito Ariza, Judit; Antunes de Melo Oliveira, Ana Mafalda; Wildiers, Hans; Brufksy, Adam M.; Waters, Simon; Vivancos Prellezo, Ana; Saura Manich, Cristina (American Association for Cancer Research, 2021-11-01) -
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Onesti, Concetta Elisa; Tagliamento, Marco; Harbeck, Nadia; Bartsch, Rupert; Wildiers, Hans; Cortés Castan, Javier; Curigliano, Giuseppe (American Society of Clinical Oncology, 2021-02-02) -
Oncological care organisation during COVID-19 outbreak
Onesti, Concetta Elisa; Generali, Daniele; Peeters, Marc; Zaman, Khalil; Wildiers, Hans; Cortés Castan, Javier; Rugo, Hope (BMJ, 2020-08-26) -
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Dieras, Veronique; Cortés Castan, Javier; Patt, Debra; Wildiers, Hans; O’Shaughnessy, Joyce; Zamora Adelantado, Esther; Rugo, Hope (Springer, 2020-11)